Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX701 plus cetuximab and chemotherapy versus placebo plus cetuximab and chemotherapy in previously treated RAS/BRAF wild-type metastatic colorectal cancer
CTR20260237Phase 2Active
- Sponsor
- Henlius Ruilin
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HLX701 in colorectal adenocarcinoma, sponsored by Henlius Ruilin. Started Mar 2026; status: active.
02
Drugs
HLX701
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20260237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260237.